High Intensity Laser Therapy
Customize your policy alerts
Sign up for blue cross blue shield - south dakota Policy 02.01.82 alerts
Get alerted when Policy 02.01.82 changes without checking for updates manually.
Monitor payer policy activity
This policy governs the medical policy determination for use of high-intensity (Class IV) laser therapy for chronic musculoskeletal pain, Bell's palsy, and other indications in Blue Cross Blue Shield - South Dakota members.
No material clinical or coverage changes in this revision.
Coverage Determination and Evidence Summary
Not covered — investigational
Coverage stance for HILT
Evidence insufficient to determine improvement in net health outcome based on randomized trials and systematic reviews with methodological limitations and heterogeneity.
Chronic musculoskeletal pain — evidence synthesis
Evidence summary and applicability
Heterogeneity in study protocols, cointerventions, and patient characteristics reduces applicability.
Effect sizes and direction vary across reviews; some outcomes show large SMDs for neck and low back pain.
These limitations preclude firm conclusions about effectiveness.
Bell's palsy — clinical context
HILT as alternative therapy for Bell's palsy
Evidence limitations for Bell's palsy and general HILT effectiveness
Evidence summary and implication
Limitations include lack of blinding, no intention-to-treat analysis, and short follow-up; natural resolution of Bell's palsy complicates interpretation.
Summary of pooled evidence
Systematic review and meta-analysis findings (umbrella review)
Appendix 1 summarizes multiple meta-analyses with I2 values ranging widely and GRADE often NR/low/very low.
The policy does not list any indications for which High Intensity Laser Therapy (HILT) is considered routinely covered. HILT is considered investigational for chronic musculoskeletal pain, Bell's palsy, and all other indications, because the evidence is insufficient to determine that the technology improves net health outcomes.
Randomized controlled trials and multiple systematic reviews report some statistically and clinically significant improvements in pain and function with HILT for certain musculoskeletal conditions, but serious methodological limitations and substantial heterogeneity in device parameters, cointerventions, and patient characteristics reduce confidence in the findings. Consequently, current evidence is insufficient to demonstrate a net health benefit for routine use of HILT.
Although some reviews report benefit for specific musculoskeletal conditions, there are no established practice guidelines defining HILT's role in chronic pain care pathways. The policy notes the relevant population is individuals who have not responded to conservative therapy (e.g., exercise, physical therapy, NSAIDs), but even in that context, routine coverage is not supported given the low-to-moderate certainty evidence, heterogeneous protocols, and trial limitations.
For Bell's palsy the available randomized evidence is limited to a single small RCT that reported greater short‑term improvement with HILT versus exercise, but study design limitations and the condition's frequent spontaneous recovery make attribution of benefit to HILT uncertain. Therefore, evidence is insufficient to determine an improvement in net health outcome for Bell's palsy.
The provided excerpts do not contain any explicit statements designating HILT as covered for particular indications; instead, the appendix and meta-analytic summaries present evidence only and do not by themselves establish coverage or exclusion rules.
Appendix materials present pooled results from systematic reviews and meta-analyses to inform policy assessment but do not define coverage criteria. These evidence summaries are presented for review and do not by themselves establish coverage or exclusion determinations.
The appendix excerpts summarize outcomes, heterogeneity, and GRADE ratings from multiple reviews but do not state explicit coverage exclusions. They are intended to inform the policy evaluation rather than to declare services not medically necessary.
Within the provided excerpts there are no conditions specifically labeled as not medically necessary; the appendix reports meta-analytic findings and heterogeneity metrics but does not itself designate any services as not medically necessary.
This portion of the appendix reports pooled effect estimates and heterogeneity (I2) across reviews but does not assert that any services are not medically necessary; it summarizes evidence to support policy deliberations.
The appendix provides definitions, outcome measures, and a note that heterogeneity is assessed by the I2 statistic, but it does not itself declare services as not medically necessary; its role is to supply evidence details for policy determination.
Billing and Coding
| 17999 | Unlisted procedures, skin, mucous membrane and subcutaneous tissue (may be utilized for high-intensity laser therapy: Diowave Laser System, ESPT-3X, K-Laser, LCT-1000, OptonPro). |
| 97039 | Unlisted modality (specify type of time if constant attendance) (may be utilized for high-intensity laser therapy: Diowave Laser System, ESPT-3X, K-Laser, LCT-1000, OptonPro). |
| 97139 | Unlisted therapeutic procedure (specify) (may be utilized for high-intensity laser therapy: Diowave Laser System, ESPT-3X, K-Laser, LCT-1000, OptonPro). |
| 99199 | Unlisted special service, procedure or report (may be utilized for high-intensity laser therapy: Diowave Laser System, ESPT-3X, K-Laser, LCT-1000, OptonPro). |
| No codes listed |
Prior Authorization, Documentation, and Billing Guidance
Denial risk and administrative expectations
High Intensity Laser Therapy (HILT) is designated investigational in this policy; evidence limitations and methodological concerns have led to insufficient confidence in effectiveness and may result in coverage denials.
- Evidence limitations (small RCTs, methodological flaws, heterogeneity of HILT parameters, limited follow-up) may trigger medical necessity or coverage denials.
- No explicit prior authorization or administrative prior approval requirement is stated in this policy (Prior Approval: Not applicable).
- No specific documentation requirements or administrative rules for HILT are described in the policy excerpts or appendix.
- Appendix 1 provides pooled outcome statistics and GRADE/quality ratings from systematic reviews and umbrella reviews that informed the policy.
- There are no described step therapy or sequencing requirements, and no explicit conservative-treatment sequencing beyond the general expectation that HILT would be considered for individuals who have not responded to conservative therapies.
Documentation expectations (recommended)
When submitting requests or clinical information related to HILT, include documentation of the diagnosis, prior conservative treatments tried, rationale for HILT, baseline and follow-up functional outcome measures when available, and any supporting evidence. Because the policy classifies HILT as investigational, high-quality evidence or new data may be needed to support coverage.
- Document prior conservative care (e.g., exercise, physical therapy, NSAIDs, corticosteroid/antiviral therapy for Bell's palsy) and duration/failure of those treatments.
- Provide baseline and follow-up outcomes (e.g., pain scores, Facial Disability Index, House-Brackmann Scale, functional measures) and timing of assessments.
- If submitting new clinical evidence or trial results, follow Wellmark submission process (address in Appendix 1 contact information).
Billing / coding guidance
Billing for HILT is commonly reported with unlisted or modality codes; providers should confirm coding and may need to supply supporting documentation when using unlisted codes.
- Potential codes that may be used: 17999 (unlisted procedure), 97039 (unlisted modality, constant attendance), 97139 (unlisted therapeutic procedure), 99199 (unlisted special service).
- Include procedure description, device used (e.g., Diowave, ESPT-3X, K-Laser, LCT-1000, OptonPro), number of units/time, and clinical rationale when billing unlisted codes.
Prior authorization and step-therapy status
Policy and appendix excerpts do not specify prior authorization, step therapy, or detailed administrative requirements for HILT. Providers should verify member benefits and any local plan-specific prior authorization rules before scheduling services.
- Prior approval: Not applicable in this policy excerpt — however, some plans or networks may require prior authorization for unlisted procedures or services billed with the codes above.
- Step therapy: No step therapy or formal sequencing requirements are described in the policy or appendix.
- Administrative requirements: No explicit administrative documentation checklist or prior authorization form is provided in these excerpts.
Prior Conservative Care and Documentation
Documented failure of conservative therapy is implied as intended population but policy considers HILT investigational regardless
Conservative therapy context and policy implication
Policy background references this population but HILT is considered investigational regardless of prior conservative therapy.
Prior conservative therapy recommended (no explicit node details provided)
Prior conservative therapy is recommended though policy remains investigational
This is a recommended documentation expectation; it does not change investigational stance.
Document prior conservative therapy and rationale for HILT use
Documentation expectations for prior therapy and rationale
Include specifics of conservative care (type, duration, response) and why HILT is being considered despite investigational status.
Conservative treatment requirements — not detailed in provided appendix
Conservative treatment requirements — appendix excerpt
Appendix focuses on pooled outcomes and methodological quality rather than operational treatment sequencing.
No conservative-treatment prerequisites described in appendix excerpt
Conservative-treatment prerequisites not specified
Policy materials note intended population as non-responders to conservative care, but the appendix provides evidence summaries only.
Conservative treatment requirements — no nodes provided in appendix
Conservative treatment requirements — absence of operational nodes
Providers should document prior care per general documentation guidance but no explicit checklist is provided in appendix excerpts.
Definitions and Background
High‑intensity laser therapy (HILT) refers to Class IV therapeutic non‑surgical lasers with power output >500 mW intended to transmit energy to deeper musculoskeletal tissues. Proposed mechanisms include photobiomodulation, photothermal effects, and possible neural inhibition or endorphin release, with the goal of reducing pain and promoting local circulation; however, these mechanisms are not well established in clinical trials and device parameters vary widely across studies.
Treatment Frequency and Imaging Requirements
Imaging requirements — none specified
No imaging requirements for HILT are specified in the policy excerpts or appendix.
- Standard imaging considerations for underlying musculoskeletal conditions are discussed for comparators, but no HILT‑specific imaging rules are stated.
Imaging requirements — not specified
The document does not specify imaging prerequisites for HILT in the provided sections.
Imaging requirements — HILT (no imaging stated)
No imaging requirements are described for HILT in the appendix or policy excerpts.
Imaging requirements — not specified in excerpt
Imaging requirements are not specified in the provided excerpted material.
Not Covered / Investigational Services
Overall policy conclusion: Use of HILT is considered investigational because current randomized trials and systematic reviews have methodological limitations and heterogeneous protocols, and the evidence is insufficient to demonstrate improved net health outcomes for chronic musculoskeletal pain and Bell's palsy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.